Title:
NOVEL PARP7 INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/006013
Kind Code:
A1
Abstract:
Disclosed are a compound serving as a PARP7 inhibitor, and a use thereof in preparing a drug for treating relevant diseases. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer.
Inventors:
YAN XIAOXIA (CN)
HUANG GUANXIN (CN)
JU WEI (CN)
SUN DAQING (CN)
HUANG GUANXIN (CN)
JU WEI (CN)
SUN DAQING (CN)
Application Number:
PCT/CN2022/108475
Publication Date:
February 02, 2023
Filing Date:
July 28, 2022
Export Citation:
Assignee:
SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN)
International Classes:
C07D403/10; A61K31/501; A61P35/00; C07D237/32
Domestic Patent References:
| WO2012019427A1 | 2012-02-16 |
Foreign References:
| US20110172415A1 | 2011-07-14 | |||
| CN1980674A | 2007-06-13 | |||
| CN111787916A | 2020-10-16 | |||
| CN101855221A | 2010-10-06 | |||
| CN102898377A | 2013-01-30 | |||
| CN103570725A | 2014-02-12 | |||
| CN106749261A | 2017-05-31 | |||
| CN202110862671A | 2021-07-29 | |||
| CN202210208759A | 2022-03-03 | |||
| CN202210839712A | 2022-07-15 |
Other References:
DATABASE REGISTRY ANONYMOUS : "1-Piperazinecarboxamide, N-(1,6-dihydro-6-oxo-3-pyridazinyl)-4-(2- pyridinyl)-(CA INDEX NAME) ", XP093029269, retrieved from STN
GOZGIT JOSEPH M.; VASBINDER MELISSA M.; ABO RYAN P.; KUNII KAIKO; KUPLAST-BARR KRISTY G.; GUI BIN; LU ALVIN Z.; MOLINA JENNIFER R.: "PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity", CANCER CELL, CELL PRESS, US, vol. 39, no. 9, 22 July 2021 (2021-07-22), US , pages 1214, XP086777352, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2021.06.018
COHENP. CHANG: "Insights into the biogenesis, function, and regulation of ADP- ribosylation", NAT CHEM BIOL, vol. 14, 2018, pages 236 - 243, XP055959252, DOI: 10.1038/nchembio.2568
S.VYAS ET AL.: "Family-wide analysis of poly(ADP-ribose) polymerase activity", NAT COMMUN, vol. 5, 2014, pages 4426, XP055959263, DOI: 10.1038/ncomms5426
A. OHMOTOS. YACHIDA: "Current status of poly(ADP-ribose) polymerase inhibitors and future directions", ONCO TARGETS THER, vol. 10, 2017, pages 5195 - 5208
E. L. GOODE ET AL.: "A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24", NAT GENET, vol. 42, 2010, pages 874 - 879, XP055603331, DOI: 10.1038/ng.668
C. BIGETSBOLL ET AL.: "TCDD-Inducible poly-ADP-ribose (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors", BIOCHEM J, vol. 473, 2016, pages 899 - 910
GOZGIT JOSEPH M.; VASBINDER MELISSA M.; ABO RYAN P.; KUNII KAIKO; KUPLAST-BARR KRISTY G.; GUI BIN; LU ALVIN Z.; MOLINA JENNIFER R.: "PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity", CANCER CELL, CELL PRESS, US, vol. 39, no. 9, 22 July 2021 (2021-07-22), US , pages 1214, XP086777352, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2021.06.018
COHENP. CHANG: "Insights into the biogenesis, function, and regulation of ADP- ribosylation", NAT CHEM BIOL, vol. 14, 2018, pages 236 - 243, XP055959252, DOI: 10.1038/nchembio.2568
S.VYAS ET AL.: "Family-wide analysis of poly(ADP-ribose) polymerase activity", NAT COMMUN, vol. 5, 2014, pages 4426, XP055959263, DOI: 10.1038/ncomms5426
A. OHMOTOS. YACHIDA: "Current status of poly(ADP-ribose) polymerase inhibitors and future directions", ONCO TARGETS THER, vol. 10, 2017, pages 5195 - 5208
E. L. GOODE ET AL.: "A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24", NAT GENET, vol. 42, 2010, pages 874 - 879, XP055603331, DOI: 10.1038/ng.668
C. BIGETSBOLL ET AL.: "TCDD-Inducible poly-ADP-ribose (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors", BIOCHEM J, vol. 473, 2016, pages 899 - 910
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: